Crcm LP Has $1.92 Million Stock Holdings in Burning Rock Biotech Limited Sponsored ADR $BNR

Crcm LP boosted its stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) by 13.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 221,575 shares of the company’s stock after buying an additional 26,809 shares during the period. Burning Rock Biotech accounts for approximately 0.5% of Crcm LP’s portfolio, making the stock its 10th largest position. Crcm LP’s holdings in Burning Rock Biotech were worth $1,917,000 at the end of the most recent reporting period.

Separately, Prospera Financial Services Inc bought a new position in shares of Burning Rock Biotech in the 3rd quarter worth approximately $214,000. 30.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BNR has been the topic of several research reports. Wall Street Zen upgraded Burning Rock Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Burning Rock Biotech Stock Down 6.6%

NASDAQ:BNR opened at $21.98 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.91 and a current ratio of 3.14. The firm has a market cap of $236.50 million, a P/E ratio of -13.24 and a beta of 1.35. Burning Rock Biotech Limited Sponsored ADR has a fifty-two week low of $2.18 and a fifty-two week high of $41.72. The firm has a 50-day simple moving average of $28.22 and a two-hundred day simple moving average of $17.94.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.